ICAHN School of Medicine At Mount Sinai

Mount Sinai Health System opens the Hamilton and Amabel James Center for AI and Human Health, a 12-story, 65,000-square-foot facility dedicated to enhancing healthcare through AI research and development, supported by a generous gift from Hamilton and Amabel James.

Gürkan Mollaoğlu's study in Cell reveals ovarian cancer-derived IL-4 promotes immunotherapy resistance, suggesting IL-4 receptor inhibitors like Dupilumab could enhance PD-1 inhibitor efficacy, offering new hope for treatment.

Mount Sinai researchers identified cost-effective LLM deployment strategies for health systems, revealing high-capacity models like Meta's Llama-3-70B and GPT-4 Turbo 128k handle up to 50 clinical tasks accurately, reducing API costs up to 17-fold and potentially saving millions annually.

RPI and Icahn Mount Sinai will offer a joint Ph.D. in health sciences engineering from fall 2025, focusing on reparative and regenerative medicine, immunoengineering, and neuroengineering. Students will undergo engineering training at RPI, clinical shadowing at Icahn Mount Sinai, and entrepreneurship training at the Center for Engineering and Precision Medicine (CEPM), aiming to produce medical innovators capable of addressing unmet clinical needs.

Tianeptine, a non-FDA-approved antidepressant, shows potential as a faster and longer-lasting treatment for neuropathic pain compared to desipramine, with fewer side effects and without the addiction risks of opioids. Research by Venetia Zachariou and her team indicates tianeptine could be a new therapeutic option, highlighting new molecular pathways for pain management.

Antelope Surgical Solutions, Inc. received FDA approval for its prostate cancer drug AS1986NS, enabling clinical trials for cancer identification and surgical margin delineation. The drug combines therapeutic and imaging radioisotopes with a fluorescent linker, enhancing surgical precision by targeting specific cancer cells. Trials are set to begin in Q1 2025, led by experts in surgical robotics, and will integrate AI for improved image-guided surgery.

Mount Sinai Health System awarded $7 million by NIH to lead NY coalition to create diverse health database, aiming to inform individualized treatment and increase participants, particularly in opioid use disorder, through collaboration with Weill Cornell Medicine, NYC Health + Hospitals, Institute for Family Health, and NYU Langone.

Mount Sinai awarded $7M by NIH to lead NY coalition for diverse health database, aiming to inform personalized treatments and address opioid crisis through increased participant recruitment.

Clemson University's Marc Birtwistle leads a $2.6M cancer research project aiming to manage tumors with drug combinations, turning them into chronic, treatable conditions. Focusing on glioblastoma, the research targets cell state shifts causing drug resistance, aiming to develop therapies that keep cancer cells in drug-sensitive states.